Centrally acting sympathomimetics

Methylphenidate Hydrochloride

Approved 14 Aug 2015OralSolution

The FDA lists this product in 60 strengths and forms.

Indications

Methylphenidate hydrochloride oral solution is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years of age and older Narcolepsy Methylphenidate hydrochloride is a central nervous system (CNS) stimulant indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years of age and older (1 ) Narcolepsy ( 1 )

Contraindications

Methylphenidate hydrochloride oral solution is contraindicated in patients: with known hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride oral solution. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate [ see Adverse Reactions ( 6 )]. receiving concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises [ see Drug Interactions ( 7 )].

Known hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride oral solution( 4 ) Concurrent treatment with a monoamine oxidase inhibitor (MAOI), or use of an MAOI within the preceding 14 days ( 4 )

Warnings and precautions

Risks to patient with Serious Cardiac Disease : Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease. ( 5.2 ) Increased Blood Pressure and Heart Rate : Monitor blood pressure and pulse. ( 5.3 ) Psychiatric Adverse Reactions : Prior to initiating methylphenidate hydrochloride oral solution, screen patients for risk factors for developing a manic episode.

If new psychotic or manic symptoms occur, consider discontinuing methylphenidate hydrochloride oral solution. ( 5.4 ) Priapism : If abnormally sustained or frequent and painful erections occur, patients should seek immediate medical attention. ( 5.5 ) Peripheral Vasculopathy, Including Raynaud's Phenomenon : Careful observation for digital changes is necessary during methylphenidate hydrochloride oral solution treatment.

Adverse reactions

The following adverse reactions are discussed in more detail in other sections of the labeling: Abuse, Misuse, and Addiction [ see Warnings and Precautions (5.1 ), Drug Abuse and Dependence ( 9.2 , 9.3 )] Known hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride oral solution [ see Contraindications ( 4 )] Hypertensive crisis when used concomitantly with monoamine oxidase inhibitors [ see Contraindications ( 4 ), Drug Interactio ns ( 7 )] Risks to patient with serious cardiac disease [ see Warnings and Precautions ( 5.2 )] Increased blood pressure and heart rate [ see Warnings and Precautions ( 5.3 )] Psychiatric adverse reactions [ see Warnings and Precautions ( 5.4 )] Priapism [ see Warnings and Precautions ( 5.5 )] Peripheral vasculopathy, including Raynaud's phenomenon [ see Warnings and Precautions ( 5.6 )] Long-term suppression of growth in pediatric patients [ see Warnings and Precautions ( 5.7 )] Acute angle closure glaucoma [see Warnings and Precautions ( 5.8 )] Increased intraocular pressure and glaucoma [see Warnings and Precautions ( 5.9 )] Motor and verbal tics, and worsening of Tourette's syndrome [see Warnings and Precautions ( 5.10 )] The following adverse reactions associated with the use of methylphenidate containing products were identified in clinical studies, postmarketing reports, or literature.

Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Infections and infestations : nasopharyngitis Blood and the lymphatic system disorders : leukopenia, thrombocytopenia, anemia, pancytopenia Immune system disorders : hypersensitivity reactions, including angioedema and anaphylaxis, auricular swelling, bullous conditions, eruptions, exanthemas Metabolism and nutrition disorders : decreased appetite, reduced weight gain and suppression of growth during prolonged use in pediatric patients Psychiatric disorders : insomnia, anxiety, restlessness, agitation, psychosis (sometimes with visual and tactile hallucinations), depressed mood, affect lability, mania, disorientation, libido changes Nervous system disorders : headache, dizziness, tremor, dyskinesia including choreoatheetoid movements, drowsiness, convulsions, cerebral arteritis and/or occlusion, serotonin syndrome in combination with serotonergic drugs, migraine Eye disorders : blurred vision, difficulties in visual accommodation, diplopia, mydriasis Cardiac disorders: tachycardia, palpitations, increased blood pressure, arrhythmias, angina pectoris, sudden cardiac death, myocardial infarction, bradycardia, extrasystole Respiratory, thoracic and mediastinal disorders: cough, pharyngolaryngeal pain, dyspnea Gastrointestinal disorders: dry mouth, nausea, vomiting, abdominal pain, dyspepsia, diarrhea General disorders: fatigue, hyperpyrexia Hepatobiliary disorders: abnormal liver function, ranging from transaminase elevation to severe hepatic injury Skin and subcutaneous tissue disorders : hyperhidrosis, pruritus, urticaria, exfoliative dermatitis, scalp hair loss, erythema multiforme rash, thrombocytopenic purpura angioneurotic edema, erythema, fixed drug eruption Musculoskeletal and connective tissue disorders : arthralgia, muscle cramps, rhabdomyolysis, myalgia, muscle twitching Renal and urinary disorders : hematuria Reproductive system and breast disorders : gynecomastia Urogenital disorders : priapism Vascular disorders : peripheral coldness, Raynaud's phenomenon Investigations : weight loss Common adverse reactions: tachycardia, palpitations, headache, insomnia, anxiety, hyperhidrosis, weight loss, decreased appetite, dry mouth, nausea, and abdominal pain.

(6) To report SUSPECTED ADVERSE REACTIONS contact Lupin Pharmaceuticals, Inc. at 1-866-403-7592 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Methylphenidate Hydrochloride

Indications

Contraindications

Warnings and precautions

Two medicines in one question?

5.1Abuse Misuse and Addiction

5.2Risks to Patient with Serious Cardiac Disease

5.3Increased Blood Pressure and Heart Rate

5.4Psychiatric Adverse Reactions Exacerbation of Pre-Existing Psychosis

5.5Priapism Prolonged

5.6Peripheral Vasculopathy, Including Raynaud’s Phenomenon

5.7Long-Term Suppression of Growth in Pediatric Patient

Interactions

7.1Clinically Important Drug Interactions with Methylphenidate Hydrochloride Oral Solution Table

Adverse reactions

Composition

Strengths and forms

Official product information

At a glance

Guidelines